Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strong sales growth for Elscint's magnetic resonance imaging (MRI) product line

This article was originally published in Clinica

Executive Summary

Israeli company Elscint's second-quarter sales were $75.4 million, up 14%. The company attributes this to increased sales of its MRI product line, which accounted for 30% of total sales, compared with 8% for the same period in the previous year. The company notes, however, that sales were hindered by the continued sluggish US market and a delay in the commercial supply of SeleCT, its spiral CT, which was introduced in December last year. In addition, previously agreed sales of equipment to China have been delayed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT088708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel